CLOs on the Move


 
Founded in 1999, Dexcom, Inc. is transforming diabetes care and management by providing superior continuous glucose monitoring (CGM) technology to help patients and healthcare professionals better manage diabetes. Since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions that are best in class - while empowering our community to take control of diabetes.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.dexcom.com
  • 6340 Sequence Drive
    San Diego, CA USA 92121
  • Phone: 888.738.3646

Executives

Name Title Contact Details
Jeffrey Dunifon
Director and Counsel - Privacy and Data Security Profile
Nicole Greene
Senior Director, Assistant General Counsel - North America Profile
Patrick Murphy
Executive Vice President- Chief Legal Officer Profile
Kaare Larson
Vice President, Intellectual Property Profile
Timothy O'Brien
Vice President, Global Legal Affairs Profile

Similar Companies

Liberty Medical Supply

Liberty Medical Supply is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Coeur Medical

Coeur Medical is a Washington, NC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Boehringer Wound Systems

Boehringer Wound Systems is a Norristown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Autocam Medical

Autocam Medical is a precision-machining contract manufacturer of highly engineered implants and instruments for surgical applications. Our product specialties include custom bone screws, bone plates and fixation devices; and perfect-fit complementary, surgical drivers, drill bits, taps and other rotary cutting instruments.

Specific Diagnostics

Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specific`s Revealâ„¢ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specific`s unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specific`s system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections. Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing.